{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:43:40Z","timestamp":1761597820260},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","brainanddevelopment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.braindev.2017.05.004","type":"journal-article","created":{"date-parts":[[2017,5,24]],"date-time":"2017-05-24T15:47:23Z","timestamp":1495640843000},"page":"756-762","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical features in very early-onset demyelinating disease with anti-MOG antibody"],"prefix":"10.1016","volume":"39","author":[{"given":"Masahiro","family":"Nishiyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Nagase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumi","family":"Tomioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Awano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsukasa","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisaku","family":"Toyoshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azusa","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Oyazato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Takada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimihiko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumoto","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.braindev.2017.05.004_b0005","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","article-title":"Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination","volume":"15","author":"Ramanathan","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.braindev.2017.05.004_b0010","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneurol.2013.118","article-title":"The spectrum of MOG autoantibody-associated demyelinating diseases","volume":"9","author":"Reindl","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.braindev.2017.05.004_b0015","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.4049\/jimmunol.0801888","article-title":"Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis","volume":"183","author":"McLaughlin","year":"2009","journal-title":"J Immunol"},{"issue":"Suppl. 4","key":"10.1016\/j.braindev.2017.05.004_b0020","doi-asserted-by":"crossref","first-page":"S326","DOI":"10.1007\/s10072-004-0335-z","article-title":"Multiple sclerosis in children under 10 years of age","volume":"25","author":"Ruggieri","year":"2004","journal-title":"Neurol Sci"},{"key":"10.1016\/j.braindev.2017.05.004_b0025","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1177\/1352458508101933","article-title":"Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States","volume":"15","author":"Chitnis","year":"2009","journal-title":"Mult Scler"},{"key":"10.1016\/j.braindev.2017.05.004_b0030","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrneurol.2009.158","article-title":"Pediatric multiple sclerosis","volume":"5","author":"Yeh","year":"2009","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.braindev.2017.05.004_b0035","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa067597","article-title":"Natural history of multiple sclerosis with childhood onset","volume":"356","author":"Renoux","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.braindev.2017.05.004_b0040","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1212\/NXI.0000000000000081","article-title":"Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children","volume":"2","author":"Hacohen","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.braindev.2017.05.004_b0045","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1177\/1352458514566666","article-title":"Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort","volume":"21","author":"Ketelslegers","year":"2015","journal-title":"Mult Scler"},{"key":"10.1016\/j.braindev.2017.05.004_b0050","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/1352458511430704","article-title":"Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis","volume":"18","author":"Chitnis","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.braindev.2017.05.004_b0055","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.braindev.2017.05.004_b0060","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.braindev.2017.05.004_b0065","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.braindev.2017.05.004_b0070","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1177\/1352458516631038","article-title":"Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): Extending the spectrum of MOG antibody positive diseases","volume":"22","author":"Baumann","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.braindev.2017.05.004_b0075","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S1474-4422(07)70242-9","article-title":"Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions","volume":"6","author":"Banwell","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.braindev.2017.05.004_b0080","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/1352458515587751","article-title":"Clinical and MRI phenotype of children with MOG antibodies","volume":"22","author":"Fernandez-Carbonell","year":"2016","journal-title":"Multiple Sclerosis J"},{"key":"10.1016\/j.braindev.2017.05.004_b0085","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.braindev.2015.02.006","article-title":"Clinical features and long-term outcome of a group of Japanese children with inflammatory central nervous system disorders and seropositivity to myelin-oligodendrocyte glycoprotein antibodies","volume":"37","author":"Hino-Fukuyo","year":"2015","journal-title":"Brain Dev"},{"key":"10.1016\/j.braindev.2017.05.004_b0090","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1055\/s-2001-17370","article-title":"Interferon beta-1a in children with multiple sclerosis is well tolerated","volume":"32","author":"Waubant","year":"2001","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.braindev.2017.05.004_b0095","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1067\/mpd.2001.117004","article-title":"Interferon-beta treatment in patients with childhood-onset multiple sclerosis","volume":"139","author":"Mikaeloff","year":"2001","journal-title":"J Pediatr"},{"key":"10.1016\/j.braindev.2017.05.004_b0100","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10072-009-0083-1","article-title":"Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience","volume":"30","author":"Ghezzi","year":"2009","journal-title":"Neurol Sci"},{"key":"10.1016\/j.braindev.2017.05.004_b0105","first-page":"97","article-title":"Interferon-beta in pediatric multiple sclerosis patients: safety in short-term prescription","volume":"50","author":"Basiri","year":"2012","journal-title":"Acta Med Iran"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760417301444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760417301444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T13:58:51Z","timestamp":1535810331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760417301444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0387760417301444"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2017.05.004","relation":{},"ISSN":["0387-7604"],"issn-type":[{"value":"0387-7604","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical features in very early-onset demyelinating disease with anti-MOG antibody","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2017.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}